Literature DB >> 12885901

Feline immunodeficiency virus ORF-Ais required for virus particle formation and virus infectivity.

Malou C Gemeniano1, Earl T Sawai, Christian M Leutenegger, Ellen E Sparger.   

Abstract

The orf-A (orf-2) gene of feline immunodeficiency virus (FIV) is a small open reading frame predicted to encode a 77-amino-acid protein that contains putative domains similar to those of the ungulate lentiviral Tat protein. Orf-A is reported to be critical for efficient viral replication in vitro and in vivo. A series of FIV-pPPR-derived proviruses with in-frame deletions and point mutations within orf-A were constructed and tested for replication in feline lymphoid cells. Orf-A mutant proviruses were also tested for viral gene and protein expression, viral particle formation, and virion infectivity. Deletions within orf-A severely restricted FIV replication in feline peripheral blood mononuclear cells (PBMC) and interleukin-2-dependent T-cell lines. In addition, substitutions of alanines for leucines in the putative leucine-rich domain, for cysteines in the putative cysteine-rich domain, and for a tryptophan at position 43 in Orf-A restricted the replication of FIV mutants. Deletions and point mutations in orf-A imposed a small effect or no effect on FIV long-terminal-repeat-driven viral gene expression and had no effect on viral protein expression. However, release of cell-free, virion-associated viral RNA in supernatants from cells transfected with orf-A mutant proviruses was severely restricted but was rescued by cotransfection with a wild-type Orf-A expression vector. In addition, virions derived from orf-A mutant proviruses expressed reduced infectivity for feline PBMC. Our findings suggest that Orf-A functions involve multiple steps of the FIV life cycle including both virion formation and infectivity. Furthermore, these observations suggest that Orf-A represents an FIV-encoded analog more similar to the accessory gene vpr, vpu, or nef than to the regulatory gene tat encoded by the primate lentiviruses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885901      PMCID: PMC167212          DOI: 10.1128/jvi.77.16.8819-8830.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Virulence differences between two field isolates of feline immunodeficiency virus (FIV-APetaluma and FIV-CPGammar) in young adult specific pathogen free cats.

Authors:  N C Pedersen; C M Leutenegger; J Woo; J Higgins
Journal:  Vet Immunol Immunopathol       Date:  2001-05-10       Impact factor: 2.046

2.  Characterisation of a tumour-specific antigen on the surface of feline lymphosarcoma cells.

Authors:  H W Snyder; W D Hardy; E E Zuckerman; E Fleissner
Journal:  Nature       Date:  1978-10-19       Impact factor: 49.962

Review 3.  Molecular biology of the feline immunodeficiency virus auxiliary genes.

Authors:  K Tomonaga; T Mikami
Journal:  J Gen Virol       Date:  1996-08       Impact factor: 3.891

4.  Binding of recombinant feline immunodeficiency virus surface glycoprotein to feline cells: role of CXCR4, cell-surface heparans, and an unidentified non-CXCR4 receptor.

Authors:  A de Parseval; J H Elder
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Construction and in vitro characterization of attenuated feline immunodeficiency virus long terminal repeat mutant viruses.

Authors:  L Bigornia; K M Lockridge; E E Sparger
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  Thymic lesions in cats infected with a pathogenic molecular clone or an ORF-A/2-deficient molecular clone of feline immunodeficiency virus.

Authors:  R M Norway; P C Crawford; C M Johnson; A Mergia
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Early pathogenesis of transmucosal feline immunodeficiency virus infection.

Authors:  Leslie A Obert; Edward A Hoover
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

8.  Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators.

Authors:  Udayan Chatterji; Aymeric de Parseval; John H Elder
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization.

Authors:  M Pistello; M Moscardini; P Mazzetti; F Bonci; L Zaccaro; P Isola; G Freer; S Specter; D Matteucci; M Bendinelli
Journal:  Virology       Date:  2002-06-20       Impact factor: 3.616

10.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Authors:  N C Pedersen; E W Ho; M L Brown; J K Yamamoto
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

View more
  20 in total

1.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Accessory genes confer a high replication rate to virulent feline immunodeficiency virus.

Authors:  Ryan M Troyer; Jesse Thompson; John H Elder; Sue VandeWoude
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

Review 3.  Going wild: lessons from naturally occurring T-lymphotropic lentiviruses.

Authors:  Sue VandeWoude; Cristian Apetrei
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 4.  Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV.

Authors:  John H Elder; Ying-Chuan Lin; Elizabeth Fink; Chris K Grant
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

5.  Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation.

Authors:  James H Morrison; Rebekah B Guevara; Adriana C Marcano; Dyana T Saenz; Hind J Fadel; Daniel K Rogstad; Eric M Poeschla
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

6.  OrfA downregulates feline immunodeficiency virus primary receptor CD134 on the host cell surface and is important in viral infection.

Authors:  Yang Hong; Elizabeth Fink; Qiong-Ying Hu; William B Kiosses; John H Elder
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

7.  Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.

Authors:  Soumi Gupta; Christian M Leutenegger; Gregg A Dean; Jonathan D Steckbeck; Kelly Stefano Cole; Ellen E Sparger
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 8.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

9.  Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins.

Authors:  Magnus Sundstrom; Udayan Chatterji; Lana Schaffer; Sohela de Rozières; John H Elder
Journal:  Virology       Date:  2007-10-25       Impact factor: 3.616

10.  Viral gene expression and provirus load of Orf-A defective FIV in lymphoid tissues and lymphocyte subpopulations of neonatal cats during acute and chronic infections.

Authors:  Janelle M Novak; P Cynthia Crawford; Holly M Kolenda-Roberts; Calvin M Johnson; Ayalew Mergia
Journal:  Virus Res       Date:  2007-07-17       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.